{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:12:22Z","timestamp":1761988342639},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10637-010-9589-x","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T09:26:10Z","timestamp":1291109170000},"page":"28-35","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The DAC system and associations with multiple myeloma"],"prefix":"10.1007","volume":"28","author":[{"given":"Enrique M.","family":"Ocio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,1]]},"reference":[{"key":"9589_CR1","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860\u20131873","journal-title":"N Engl J Med"},{"key":"9589_CR2","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1200\/JCO.2009.26.6171","volume":"27","author":"NJ Petrelli","year":"2009","unstructured":"Petrelli NJ, Winer EP, Brahmer J et al (2009) Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening\u2013a report from the American Society of Clinical Oncology. J Clin Oncol 27:6052\u20136069","journal-title":"J Clin Oncol"},{"key":"9589_CR3","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111:2962\u20132972","journal-title":"Blood"},{"key":"9589_CR4","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"9589_CR5","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"9589_CR6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565\u20131571","journal-title":"N Engl J Med"},{"key":"9589_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132","journal-title":"N Engl J Med"},{"key":"9589_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133\u20132142","journal-title":"N Engl J Med"},{"key":"9589_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S1470-2045(08)70304-8","volume":"9","author":"EM Ocio","year":"2008","unstructured":"Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF (2008) New drugs in multiple myeloma: mechanisms of action and phase I\/II clinical findings. Lancet Oncol 9:1157\u20131165","journal-title":"Lancet Oncol"},{"key":"9589_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1053\/j.seminhematol.2009.02.003","volume":"46","author":"CS Mitsiades","year":"2009","unstructured":"Mitsiades CS, Hideshima T, Chauhan D et al (2009) Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 46:166\u2013175","journal-title":"Semin Hematol"},{"key":"9589_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","volume":"338","author":"IV Gregoretti","year":"2004","unstructured":"Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17\u201331","journal-title":"J Mol Biol"},{"key":"9589_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","volume":"5","author":"M Dokmanovic","year":"2007","unstructured":"Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981\u2013989","journal-title":"Mol Cancer Res"},{"key":"9589_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/BJ20021321","volume":"370","author":"AJ de Ruijter","year":"2003","unstructured":"de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737\u2013749","journal-title":"Biochem J"},{"key":"9589_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277:8\u201321","journal-title":"Cancer Lett"},{"key":"9589_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"9589_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38\u201351","journal-title":"Nat Rev Cancer"},{"key":"9589_CR17","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541\u20135552","journal-title":"Oncogene"},{"key":"9589_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","volume":"417","author":"C Hubbert","year":"2002","unstructured":"Hubbert C, Guardiola A, Shao R et al (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455\u2013458","journal-title":"Nature"},{"key":"9589_CR19","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1242\/jcs.03431","volume":"120","author":"AD Tran","year":"2007","unstructured":"Tran AD, Marmo TP, Salam AA et al (2007) HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 120:1469\u20131479","journal-title":"J Cell Sci"},{"key":"9589_CR20","doi-asserted-by":"publisher","first-page":"26729","DOI":"10.1074\/jbc.C500186200","volume":"280","author":"P Bali","year":"2005","unstructured":"Bali P, Pranpat M, Bradner J et al (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729\u201326734","journal-title":"J Biol Chem"},{"key":"9589_CR21","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M Esteller","year":"2008","unstructured":"Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148\u20131159","journal-title":"N Engl J Med"},{"key":"9589_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","volume":"9","author":"W Weichert","year":"2008","unstructured":"Weichert W, Roske A, Gekeler V et al (2008) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9:139\u2013148","journal-title":"Lancet Oncol"},{"key":"9589_CR23","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-07-0990","volume":"14","author":"W Weichert","year":"2008","unstructured":"Weichert W, Roske A, Niesporek S et al (2008) Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14:1669\u20131677","journal-title":"Clin Cancer Res"},{"key":"9589_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","volume":"98","author":"W Weichert","year":"2008","unstructured":"Weichert W, Roske A, Gekeler V et al (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604\u2013610","journal-title":"Br J Cancer"},{"key":"9589_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194\u2013202","journal-title":"Nat Rev Cancer"},{"key":"9589_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2164-7-90","volume":"7","author":"H Ozdag","year":"2006","unstructured":"Ozdag H, Teschendorff AE, Ahmed AA et al (2006) Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7:90","journal-title":"BMC Genomics"},{"key":"9589_CR27","first-page":"117","volume":"29","author":"T Sakuma","year":"2006","unstructured":"Sakuma T, Uzawa K, Onda T et al (2006) Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29:117\u2013124","journal-title":"Int J Oncol"},{"key":"9589_CR28","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1038\/sj.onc.1208646","volume":"24","author":"S Saji","year":"2005","unstructured":"Saji S, Kawakami M, Hayashi S et al (2005) Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24:4531\u20134539","journal-title":"Oncogene"},{"key":"9589_CR29","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","volume":"10","author":"Z Zhang","year":"2004","unstructured":"Zhang Z, Yamashita H, Toyama T et al (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10:6962\u20136968","journal-title":"Clin Cancer Res"},{"key":"9589_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/jcb.20604","volume":"96","author":"BE Linggi","year":"2005","unstructured":"Linggi BE, Brandt SJ, Sun ZW, Hiebert SW (2005) Translating the histone code into leukemia. J Cell Biochem 96:938\u2013950","journal-title":"J Cell Biochem"},{"key":"9589_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1615\/CritRevEukarGeneExpr.v15.i3.30","volume":"15","author":"Y Choi","year":"2005","unstructured":"Choi Y, Elagib KE, Goldfarb AN (2005) AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein. Crit Rev Eukaryot Gene Expr 15:207\u2013216","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"9589_CR32","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1128\/MCB.21.19.6470-6483.2001","volume":"21","author":"JM Amann","year":"2001","unstructured":"Amann JM, Nip J, Strom DK et al (2001) ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21:6470\u20136483","journal-title":"Mol Cell Biol"},{"key":"9589_CR33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.bbrc.2006.05.047","volume":"345","author":"A Atsumi","year":"2006","unstructured":"Atsumi A, Tomita A, Kiyoi H, Naoe T (2006) Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 345:1471\u20131480","journal-title":"Biochem Biophys Res Commun"},{"key":"9589_CR34","doi-asserted-by":"publisher","first-page":"8777","DOI":"10.1038\/sj.onc.1208128","volume":"23","author":"A Chauchereau","year":"2004","unstructured":"Chauchereau A, Mathieu M, de Saintignon SJ et al (2004) HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene 23:8777\u20138784","journal-title":"Oncogene."},{"key":"9589_CR35","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","volume":"112","author":"W Xiong","year":"2008","unstructured":"Xiong W, Wu X, Starnes S et al (2008) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112:4235\u20134246","journal-title":"Blood"},{"key":"9589_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.leu.2404413","volume":"21","author":"NC Gutierrez","year":"2007","unstructured":"Gutierrez NC, Castellanos MV, Martin ML et al (2007) Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21:143\u2013150","journal-title":"Leukemia"},{"key":"9589_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","volume":"105","author":"H Chang","year":"2005","unstructured":"Chang H, Qi C, Yi QL, Reece D, Stewart AK (2005) p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105:358\u2013360","journal-title":"Blood"},{"key":"9589_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.leu.2404524","volume":"21","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Price-Troska T, Gonzalez-Paz N et al (2007) Clinical significance of TP53 mutation in myeloma. Leukemia 21:582\u2013584","journal-title":"Leukemia"},{"key":"9589_CR39","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1182\/blood-2008-09-177774","volume":"113","author":"EM Ocio","year":"2009","unstructured":"Ocio EM, Maiso P, Chen X et al (2009) Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113:3781\u20133791","journal-title":"Blood"},{"key":"9589_CR40","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/1535-7163.MCT-05-0446","volume":"5","author":"EM Hurt","year":"2006","unstructured":"Hurt EM, Thomas SB, Peng B, Farrar WL (2006) Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 5:1154\u20131160","journal-title":"Cancer Biol Ther"},{"key":"9589_CR41","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1182\/blood-2006-11-053728","volume":"110","author":"EL Davenport","year":"2007","unstructured":"Davenport EL, Moore HE, Dunlop AS et al (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 110:2641\u20132649","journal-title":"Blood"},{"key":"9589_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4161\/cc.7.7.5615","volume":"7","author":"EL Davenport","year":"2008","unstructured":"Davenport EL, Morgan GJ, Davies FE (2008) Untangling the unfolded protein response. Cell Cycle 7:865\u2013869","journal-title":"Cell Cycle"},{"key":"9589_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.molcel.2004.12.021","volume":"17","author":"EJ Bennett","year":"2005","unstructured":"Bennett EJ, Bence NF, Jayakumar R, Kopito RR (2005) Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17:351\u2013365","journal-title":"Mol Cell"},{"key":"9589_CR44","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0962-8924(00)01852-3","volume":"10","author":"RR Kopito","year":"2000","unstructured":"Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524\u2013530","journal-title":"Trends Cell Biol"},{"key":"9589_CR45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","volume":"115","author":"Y Kawaguchi","year":"2003","unstructured":"Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727\u2013738","journal-title":"Cell"},{"key":"9589_CR46","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1021\/jm0303094","volume":"46","author":"TA Miller","year":"2003","unstructured":"Miller TA, Witter DJ, Belvedere S (2003) Histone deacetylase inhibitors. J Med Chem 46:5097\u20135116","journal-title":"J Med Chem"},{"key":"9589_CR47","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1517\/13543784.16.5.659","volume":"16","author":"WK Rasheed","year":"2007","unstructured":"Rasheed WK, Johnstone RW, Prince HM (2007) Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16:659\u2013678","journal-title":"Expert Opin Investig Drugs"},{"key":"9589_CR48","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1073\/pnas.0430973100","volume":"100","author":"SJ Haggarty","year":"2003","unstructured":"Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100:4389\u20134394","journal-title":"Proc Natl Acad Sci USA"},{"key":"9589_CR49","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG et al (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101:4055\u20134062","journal-title":"Blood"},{"key":"9589_CR50","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1073\/pnas.2536759100","volume":"101","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540\u2013545","journal-title":"Proc Natl Acad Sci USA"},{"key":"9589_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ajh.1174","volume":"68","author":"D Lavelle","year":"2001","unstructured":"Lavelle D, Chen YH, Hankewych M, DeSimone J (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68:170\u2013178","journal-title":"Am J Hematol"},{"key":"9589_CR52","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood-2003-01-0233","volume":"102","author":"L Catley","year":"2003","unstructured":"Catley L, Weisberg E, Tai YT et al (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102:2615\u20132622","journal-title":"Blood"},{"key":"9589_CR53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2141.2004.04882.x","volume":"125","author":"SB Khan","year":"2004","unstructured":"Khan SB, Maududi T, Barton K, Ayers J, Alkan S (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125:156\u2013161","journal-title":"Br J Haematol"},{"key":"9589_CR54","first-page":"248","volume":"91","author":"M Kaiser","year":"2006","unstructured":"Kaiser M, Zavrski I, Sterz J et al (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91:248\u2013251","journal-title":"Haematologica"},{"key":"9589_CR55","first-page":"573","volume":"30","author":"C Schwartz","year":"2007","unstructured":"Schwartz C, Palissot V, Aouali N et al (2007) Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol 30:573\u2013582","journal-title":"Int J Oncol"},{"key":"9589_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12185-008-0226-9","volume":"89","author":"K Kitazoe","year":"2009","unstructured":"Kitazoe K, Abe M, Hiasa M et al (2009) Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol 89:45\u201357","journal-title":"Int J Hematol"},{"key":"9589_CR57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2008.07387.x","volume":"143","author":"P Neri","year":"2008","unstructured":"Neri P, Tagliaferri P, Di Martino MT et al (2008) In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 143:520\u2013531","journal-title":"Br J Haematol"},{"key":"9589_CR58","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","volume":"108","author":"L Catley","year":"2006","unstructured":"Catley L, Weisberg E, Kiziltepe T et al (2006) Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108:3441\u20133449","journal-title":"Blood"},{"key":"9589_CR59","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","volume":"66","author":"P Maiso","year":"2006","unstructured":"Maiso P, Carvajal-Vergara X, Ocio EM et al (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781\u20135789","journal-title":"Cancer Res"},{"key":"9589_CR60","doi-asserted-by":"crossref","unstructured":"Ocio EM, Vilanova D, Atadja P et al (2009) In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica","DOI":"10.3324\/haematol.2009.015495"},{"key":"9589_CR61","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06772.x","volume":"139","author":"R Feng","year":"2007","unstructured":"Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S (2007) The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 139:385\u2013397","journal-title":"Br J Haematol"},{"key":"9589_CR62","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/sj.bjc.6604025","volume":"97","author":"J Arts","year":"2007","unstructured":"Arts J, Angibaud P, Marien A et al (2007) R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 97:1344\u20131353","journal-title":"Br J Cancer"},{"key":"9589_CR63","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-08-0183","volume":"7","author":"R Feng","year":"2008","unstructured":"Feng R, Ma H, Hassig CA et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 7:1494\u20131505","journal-title":"Mol Cancer Ther"},{"key":"9589_CR64","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/leu.2009.121","volume":"23","author":"S Deleu","year":"2009","unstructured":"Deleu S, Lemaire M, Arts J et al (2009) The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 23:1894\u20131903","journal-title":"Leukemia"},{"key":"9589_CR65","doi-asserted-by":"crossref","unstructured":"Todoerti K, Barbui V, Pedrini O et al Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 95:260\u2013269","DOI":"10.3324\/haematol.2009.012088"},{"key":"9589_CR66","unstructured":"Mandl-Weber S, Meinel F, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol"},{"key":"9589_CR67","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1593\/neo.04655","volume":"7","author":"TE Fandy","year":"2005","unstructured":"Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7:646\u2013657","journal-title":"Neoplasia"},{"key":"9589_CR68","first-page":"3876","volume":"62","author":"M Akiyama","year":"2002","unstructured":"Akiyama M, Hideshima T, Hayashi T et al (2002) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62:3876\u20133882","journal-title":"Cancer Res"},{"key":"9589_CR69","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1128\/MCB.01481-08","volume":"29","author":"S Chen","year":"2009","unstructured":"Chen S, Dai Y, Pei XY, Grant S (2009) Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 29:6149\u20136169","journal-title":"Mol Cell Biol"},{"key":"9589_CR70","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","volume":"93","author":"JS Damiano","year":"1999","unstructured":"Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658\u20131667","journal-title":"Blood"},{"key":"9589_CR71","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585\u2013598","journal-title":"Nat Rev Cancer"},{"key":"9589_CR72","first-page":"2774","volume":"112","author":"JL Wolf","year":"2008","unstructured":"Wolf JL, Siegel D, Matous J et al (2008) A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. ASH Annu Meet Abstr 112:2774","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR73","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10428190701817258","volume":"49","author":"P Richardson","year":"2008","unstructured":"Richardson P, Mitsiades C, Colson K et al (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49:502\u2013507","journal-title":"Leuk Lymphoma"},{"key":"9589_CR74","doi-asserted-by":"crossref","unstructured":"Galli M, Salmoiraghi S, Golay J et al A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 89:185\u2013190","DOI":"10.1007\/s00277-009-0793-8"},{"key":"9589_CR75","first-page":"2574-","volume":"106","author":"R Niesvizky","year":"2005","unstructured":"Niesvizky R, Ely S, DiLiberto M et al (2005) Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM). ASH Annu Meet Abstr 106:2574-","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR76","doi-asserted-by":"crossref","unstructured":"Campbell RA, Sanchez E, Steinberg J et al Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 84:201\u2013211","DOI":"10.1111\/j.1600-0609.2009.01384.x"},{"key":"9589_CR77","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","volume":"69","author":"S Deleu","year":"2009","unstructured":"Deleu S, Lemaire M, Arts J et al (2009) Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69:5307\u20135311","journal-title":"Cancer Res"},{"key":"9589_CR78","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1073\/pnas.0503221102","volume":"102","author":"T Hideshima","year":"2005","unstructured":"Hideshima T, Bradner JE, Wong J et al (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567\u20138572","journal-title":"Proc Natl Acad Sci USA"},{"key":"9589_CR79","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","volume":"10","author":"XY Pei","year":"2004","unstructured":"Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839\u20133852","journal-title":"Clin Cancer Res"},{"key":"9589_CR80","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","volume":"15","author":"A Badros","year":"2009","unstructured":"Badros A, Burger AM, Philip S et al (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15:5250\u20135257","journal-title":"Clin Cancer Res"},{"key":"9589_CR81","first-page":"871","volume":"112","author":"D Weber","year":"2008","unstructured":"Weber D, Badros AZ, Jagannath S et al (2008) Vorinostat plus bortezomib for the treatment of relapsed\/refractory multiple myeloma: early clinical experience. ASH Annu Meet Abstr 112:871","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR82","first-page":"3711","volume":"112","author":"DM Weber","year":"2008","unstructured":"Weber DM, Jagannath S, Sobecks R et al (2008) Combination of vorinostat plus bortezomib for the treatment of patients with multiple myeloma who have previously received bortezomib. ASH Annu Meet Abstr 112:3711","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR83","first-page":"3852-","volume":"114","author":"JF San-Miguel","year":"2009","unstructured":"San-Miguel JF, Sezer O, Siegel D et al (2009) A phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma. ASH Annu Meet Abstr 114:3852-","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR84","first-page":"3698","volume":"112","author":"SJ Harrison","year":"2008","unstructured":"Harrison SJ, Quach H, Yuen K et al (2008) High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I\/II clinical trial. ASH Annu Meet Abstr 112:3698","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR85","first-page":"306-","volume":"114","author":"PM Voorhees","year":"2009","unstructured":"Voorhees PM, Gasparetto C, Richards KL et al (2009) Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed\/refractory multiple myeloma: results of a phase I study. ASH Annu Meet Abstr 114:306-","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR86","doi-asserted-by":"crossref","unstructured":"Spencer A, Lonial S, Taylor K et al (2009) Panobinostat and lenalidomide combination phase I trial in myeloma. Clin Lymphoma Myeloma. Abstract 329","DOI":"10.1016\/S1557-9190(11)70543-1"},{"key":"9589_CR87","first-page":"305-","volume":"114","author":"D Siegel","year":"2009","unstructured":"Siegel D, Weber DM, Mitsiades CS et al (2009) Combined vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a phase I study. ASH Annu Meet Abstr 114:305-","journal-title":"ASH Annu Meet Abstr"},{"key":"9589_CR88","first-page":"1855-","volume":"114","author":"JR Berenson","year":"2009","unstructured":"Berenson JR, Yellin O, Boccia RV, Nassir Y, Rothstein S, Swift RA (2009) A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). ASH Annu Meet Abstr 114:1855-","journal-title":"ASH Annu Meet Abstr"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9589-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9589-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10637-010-9589-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9589-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T16:10:54Z","timestamp":1711987854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9589-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":88,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9589"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9589-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"27 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}